Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Infigratinib
open-in-new
<p>Infigratinib is an <a href="/facts/Kinase_inhibitor/uG5lnQ3C">kinase inhibitor</a> in development for the treatment of <a href="/facts/Achondroplasia/oPT4mfxb">achondroplasia</a> and <a href="/facts/Hypochondroplasia/4SHEgp66">hypochondroplasia</a>. </p><p>Infigratinib targets the fibroblast growth factor receptors <a href="/facts/FGFR1/hrqFpqYk">FGFR1</a>, <a href="/facts/FGFR2/9lK7md1u">FGFR2</a>, and <a href="/facts/FGFR3/LTEcKdeY">FGFR3</a>. </p><p>Infigratinib was originally approved at a higher dose for medical use in the United States in May 2021 for cholangiocarcinoma, but is no longer marketed for that indication due to difficulties commercializing in the indication. </p>